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Infections During Low-Dose Methotrexate Treatment
in Rheumatoid Arthritis
Agnes M. Th. Boerbooms, Pit J.S.M. Kerstens, Jos W.A. van Loenhout, Jan Mulder,
and Leo B.A. van de Putte
We studied the infection rate in patients with rheumatoid arthritis (RA) treated 
with low-dose methotrexate (MTX) in a 6-year open prospective study and in a 
12-month randomized double blind trial comparing MTX with azathioprine 
(AZA) that was followed by a 3-year open prospective study. The literature on 
infections during low dose MTX in RA was reviewed. We also did a search for 
therapy-related opportunistic infections in RA and in MTX-treated psoriasis and 
psoriatic arthropathy patients. In our studies the infection rate during MTX 
treatment was higher in severe RA than in moderate RA. In severe RA there 
were often 2 infections simultaneously. The majority of the infections occurred 
in the first 1.5 years of treatment. There was no difference in the infection rate of 
MTX and AZA in the comparative trial. In the literature the infection rate was 
highest in short-term double-blind studies. Opportunistic infections are increas­
ingly reported in RA treated with MTX and rarely with AZA, cyclosporine A, and 
cyclophosphamide or in MTX treated psoriasis and psoriatic arthropathy. In RA 
it appears that the initial period of treatment with MTX is the most vulnerable 
phase for infections, with the exception of opportunistic infections, which are 
not limited to a certain treatment period. Probably there are more MTX- 
associated infections in severe RA than in moderate RA.
Copyright © 1995by W.B. Saunders Company
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OW-DOSE methotrexate (MTX) has be­
come a standard treatment for rheumatoid 
arthritis (RA).1'34 Its popularity is due to several 
factors such as a rapid onset of action and a 
favorable side-effect profile compared with that 
of other disease-modifying antirheumatic drugs 
(DMARDs). In addition there is extensive expe­
rience with MTX in the treatment of psoriasis 
and psoriatic arthropathy.35'37 The dose-sched­
ule usually used in RA  is derived from that for 
psoriasis. Therefore it might be assumed that 
the MTX side-effect profile is comparable in 
RA and psoriasis. However some years ago 
reports emerged indicating that MTX was asso­
ciated with more opportunistic infections38-49 
and probably more perioperative bacterial in­
fections in patients with RA.50-54 We also had 
the impression that more infections occurred 
in our MTX-treated patients than with other 
DMARDs, such as hydroxychloroquin, gold, 
D-penicillamine and azathioprine (AZA). Be­
cause we had two ongoing prospective stud­
ies with MTX,15’27 we reviewed our data on this 
subject. We also reviewed the literature on 
infectious complications during oral low-dose 
MTX treatment in RA  patients over the last 25 
years. Moreover, a separate search was per­
formed for opportunistic infections occurring
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during treatment with immunomodulating drugs 
such as low-dose MTX, AZA, or cyclosporine A 
in RA, and for treatment with MTX in psoriasis 
and psoriatic arthropathy.
In this paper we try to answer the following 
questions: (1) Was there a substantial increase 
of infections in our RA  patients treated with 
low dose MTX compared with A ZA  treat­
ment?27 (2) Can risk factors be indentified for 
these infectious complications. (3) What is the 
infection rate in MTX-treated RA  patients in 
the literature? (4) Are there more opportunistic 
infections reported in patients treated with 
MTX compared with AZA  or cyclosporine A? 
(5) What is the incidence of opportunistic 
infections in patients with psoriasis or psoriatic 
arthropathy treated with (oral) MTX?
PATIENTS AND METHODS
Two sets of data on R A patients were used in 
this study: a prospective 6-year open label study 
of MTX15»16 and a 12-month randomized double­
blind trial comparing MTX and AZA27 in a 
4-year prospective study. All patients met the 
American Rheumatism Association (ARA) cri­
teria for RA.55 The demographic characteristics 
at entry are given in Table 1. The patients in the 
open study were in a later phase of disease and 
generally had more severe RA  those in the
double-blind study. This was reflected by a 
longer disease duration, higher percentages of 
Steinbrocker functional class III, more subcuta­
neous nodules, and higher frequency of artho- 
plasty. Patients in the open study were treated 
more often with prednisone as they were either 
unresponsive to or had side effects from all 
standard DMARDs. At a minimum, patients in 
the double-blind study had received intramuscu­
lar gold. Because the risk for infection may 
increase in cases of immunodeficiency, we stud­
ied serum immunoglobulin (Ig) M, IgG, and 
IgA levels.
Since infections vary from the common flu to 
life-threatening sepsis, and because the minor 
infections were less consistently reported, we 
arbitrarily classified them as major or minor 
according to clinical importance. We defined 
major infections as those that required antibi­
otic treatment. Uncomplicated lower urinary 
tract infections were excluded (except those 
with signs of systemic involvement, such as high 
fever), because they are relative frequent in 
women with RA56 and because their occurrence 
is dependent on other factors such as impaired 
self hygiene and hormonal changes. In general, 
lower urinary infections have little clinical impor­
tance, are often treated by the general physi­
cian, and are not well documented in the
i
Table 1 : Characteristics of Patients With RA at Baseline
Open
Prospective
Study15'16
MTX
Double-Blind
Randomized
Study27
MTX AZA
No. 16 31 33
Age (yr, mean [range]) 59 (45-70) 57,3 (38-71) 55.8 (34-71)
Disease duration (years, mean [range]) 16 (5-33) 12.8 (1.5-40) 9.4(1.5-26.5)
Female/male 9/7 26/5* 17/16*
Steinbrocker functional class ll/lll
(N [%]) 7/9 (44/56) 25/6(79/21) 26/7 (81/19)
HLA-DR4 positive (%) 9(56) T9 (57) 22 (60)
Rheumatoid factor positive (% )t 14 (88) 29 (94) 33(100)
Previous arthroplasty (%)+ 5 (38) 7 (23) 7 (21)
Subcutaneous nodules (%) 14 (88) 11 (36) 11 (33)
Prednisone (n [%])§ 8(50) 2(6) 2(6)
NOTE. Unless Indicated otherwise, values are the number of patients,
*P -  .01, between MTX and AZA group in the double-blind randomized study. 
tLatex fixation titer > 1/80. 
iH rp, knee or shoulder.
§Ten milligrams or less dally.
Abbreviations: MTX, methotrexate; AZA, azathioprine.
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clinical record. All viral upper airway infections, 
fungal infections of the superficial skin and nails 
were also considered minor infections. Ex­
amples of major infections are pneumonia, 
sepsis, septic arthritis, soft tissue infections, and 
symptomatic urinary tract infections. For this 
analysis only major infections were considered. 
Patients experiencing major infections during 
leukopenic states ( <3.5 x 109/L) at the time of 
diagnosis were excluded.
In both studies patients were questioned 
about the occurrence of infections monthly 
during the first 6 months and every 2 months 
thereafter. They were specifically asked about 
episodes of fever, diarrhea, skin abnormalities, 
cough and dysuria. Visits to the general physi­
cian and the use of antimicrobial therapy were 
noted. When no conclusion could be drawn 
from this information, verification was sought 
by contacting the practitioner.
The infection incident rates were expressed 
as percentages by dividing the number of major 
infections by patients years on MTX for all 
patients per study group and multiplying by 100.
LITERATURE
Two literature searches were made using the 
MEDLINE data bases from January 1966 to 
January 1994 and BIOS data bases from Janu­
ary 1970 to January 1994. The first search was 
directed at infectious complications of MTX 
therapy in general in RA. The search terms 
were: RA, MTX, infections (complications), 
open and controlled studies. Studies accepted 
for analysis had to contain information on the 
following items: the number of MTX patients at 
risk, duration of follow-up (per patient or group), 
number and types of infections, MTX dosage, 
concommitant immunosuppressive therapy, and 
other diseases or conditions, such as malignancy 
and leukopenia, associated with an increased 
susceptibility to infection. Only the data from 
patients who had no other identifiable reason to 
be prone to major infections, except the conco­
mittant use of low dose prednisone ( < 20 mg 
daily) were used in this study. If more than one 
report of a particular study existed the latest 
update was used. When only intervals of a study 
were reported they were entered separately. 
The infection incident rate was calculated in the 
same way as our data (above).
In the second search the headings MTX, 
AZA, Cyclosporine A, opportunistic infections, 
RA, psoriasis and psoriatic arthropathy were 
used. Also the individual infections, i.e. pneumo- 
cystis carinii, herpes zoster, disseminated her­
pes simplex, cytomegalic virus, histoplasmosis, 
tuberculosis, aspergillosis, nocardia and crypto­
coccosis in combination with RA, psoriasis, 
psoriatic arthropathy were checked. To be ac­
ceptable for this part of the study reports had to 
contain information on the patient’s treatment, 
hematologic status, and the absence of other 
causes of opportunistic infections (except for 
use of low dose steroids).
Citations were limited to those in English. To 
validate the literature search, a manual search 
for additional citations using references in ar­
ticles retrieved from the computerized search, 
as well as review articles, textbooks and proceed­
ings from symposia and congresses was accom­
plished* Studies were reviewed by two of the 
authors (JvL and AB), and discrepancies be­
tween reviewers about the retrieved data were 
settled by consensus.
STATISTICS
In the double-blind study differences in demo­
graphic characteristics between the two treat­
ment groups were determined using x2 tests for 
nominal variables; for other features, such as 
age and disease duration, the Student two- 
sample test was used. For comparison of infec­
tions in the three patient groups, probability 
curves (infection free survival curves) were 
constructed, plotting the initial episode of infec­
tion against the length of time after the start of 
MTX or AZA, using the Kaplan-Meier method. 
Differences were tested with the Wilcoxon test 
for censored observations.57
RESULTS
Three treatment groups were studied: 16 
patients were started on MTX in an open 
prospective study and 31 were given MTX and 
33 AZA in a 48 week double blind randomized 
trial followed by 3 years open extension (Table 
1). Major infections were observed in all three 
treatment groups and occurred mainly in the 
first 1,5 years after which they occurred sporadi­
cally (Fig 1). In the AZA group the censoring 
pattern was different from the other two groups.
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Fig 1 : The survival prob­
ability that infection did 
not develop in patients 
with RA treated with MTX 
or AZA. No significant dif­
ferences between the 
curves (/> = .96} were pre­
sent. *Two simultaneous 
infections in the same pa­
tient.
MONTHS AFTER START THERAPY
In the AZA group 13 of 33 patients were 
dropped because of various side effects within 
the first 6 months of treatment. There were no 
significant differences among the 3 Kaplan- 
Meier infection free survival curves. In the open 
MTX study 4 of the 5 patients with infection 
had 2 infections simultaneously. In the double 
blind study no simultaneous infections oc­
curred.
The incident infection rate during 4 years of 
follow-up was 18% in the open study, and 1% in 
the MTX and AZA  groups in the double blind 
study (Table 2). Apart from 2 patients with 
herpes zoster in the open study and 1 in the 
AZA group, no opportunistic infections oc­
curred. The infections which occurred were in 
order of frequency: pneumonia (4 in the MTX 
group and 2 in the A ZA  group of the double
blind study); skin/soft tissue infection (3 in the 
MTX group of the open study and 1 in the AZA 
group of the double-blind study), complicated 
urinary tract infection (2 in the MTX group of 
the open study and 1 in the MTX group of the 
double blind study). One patient in the MTX 
double-blind study developed peritonitis; in the 
open MTX study 1 septic arthritis and 1 in­
fected knee prosthesis were identified. There 
were no fatalities. In 2 cases MTX treatment 
was permanently abandoned after the infec­
tious episode. In the other patients MTX was 
reinstituted after recovery from the infection, 
mostly in lower doses, and infection did not 
recur. At the time of infection the serum immu­
noglobulins (IgM, IgG, IgA) were normal, ex­
cept in one patient with Escherichia coli urosep­
sis, whose IgG was 8.55 g/L (N 12.5 ±2.1 g/L).
Table 2: Infection Rate During the 6-Year Open Prospective MTX Therapy Study and the 48-Week
Double-Blind Comparative Study With 3-Year Open Extension of MTX and AZA
Study Period 
(mo)
Open Study
Double-Blind Comparative Study 
With Open Extension
MTX MTX AZA
No. of 
Patients*
Patient 
Years 
on MTX
Infection
Ratet
No. of 
Patients*
Patient 
Years 
on MTX
Infection
Ratet
No. of 
Patients*
Patient 
Years 
on AZA
Infection
Ratet
0-12 16(12) 13 15 31 (21) 28 18 33 (19) 18 11
0-48 16(6) 44 18 31 (12) 87 7 33 (5) 40 7
0-72 16(6) 57 16
Abbreviations: MTX, methotrexate; AZA, azthioprine.
*Number of patients at the start of the period concerned, in parenthesis the number of patients continuing the same drug at the end of 
the period.
tlnfection rate = (number of infections/patient years at risk) x 100.
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RA and MTX Literature Search
The literature search of MTX and infections 
resulted in 45 entries. The main reasons for 
discarding studies from final analysis were: par­
enteral use of MTX (n = 4), stating side effects 
by organ system only (n = 3), inability to calcu­
late the time at risk and/or uncertainty about 
the MTX dose (n = 2) and the use of dosages 
over 15/mg per week (n = 2); 7 entries from 
ongoing studies were eliminated because the 
data were included in studies on long-term 
treatment with MTX and already included in 
the analysis. For the final analysis 27 studies 
remained, including 21 prospective (13 open, 7 
double blind, and 1 double blind at the start 
with an open extension) and 6 retrospective 
studies. It was assumed that all infections oc­
curred in the presence of normal leukocyte 
counts if not otherwise stated. There appeared
to be a slight increase in the infection rate since 
1985 (Table 3). In the 6 retrospective studies 
the mean infection rate was 1,8%, in the 13 
open prospective studies it was 4.6% and in the 
8 double-blind studies it was 11.6% (Table 4). 
The mean disease duration in the three types of 
studies did not differ substantially: 13.8, 12.9 
and 10.7 years, respectively. Mean patient years 
during MTX treatment was 336 years (range 
22.5-780) in the retrospective studies, 103 years 
(range 13-480) in the open studies and 31 years 
(range 7.4-103) in the double-blind studies 
(Table 3).
OppoHunistic Infections in RA Patients Treated 
With MTX, AZA or Cyclosporine
The search for opportunistic infections in 
patients with RA  treated with MTX produced 
19 reports. Four of these could not be used, 2
Table 3: MTX Treatment and Infection Rate in RA Patients
Disease Duration MTX Patient Infection
Patients at (yrj at MTX Start, mg/wk Years Rate
Study Design Risk (n) (Mean [range]) range on MTX (%)
Wilkens, 19801 0 32 NM (4-45) 7.5-15 47 0
Steinsson, 19823 0 21 9 (1.5-32) 7.5-25 13 0
Groff, 19834 R 28 14(5-40) 2-30 29 7
Williams, 19855 DB 95 14 (NM) 7.5-15 21 0
Weinstein, 19856 R 21 9(1.5-32) 7.5-15 53 2
Weinblatt, 19857 DB 33 10 (1.8-29) 7.5-15 7 27
Kremer, 198611 0 21 12 (8-33) 5-17.5 61 2
Hamdy, 198710 DB 21 9 (NM) 5-1S 33 0
Gispen, 198712 O 72 14 (SD 8.1) 2.5-12.5 72 3
Kremer, 198813 0 25 11 (3.8-18) Mean 14.6 50 0
Weinblatt, 198814 0 26 9 (1.8-27) 5-15 44 9
Boerbooms, 198815 0 16 16 (5-33) 5-15 14 15
Alarcon, 198918 0 152 19 (SD 15.2) Mean 7.7 480 0
Hanrahan, 198919 0 128 13 (1-46) 5-25 230 2
McKendry, 198917 R 131 NM Mean 8.4 23 0
Fürst, 198920 DB 30 NM 7.5-35 13 23
Arnold, 199021 DB 26 14 {SD 8) NM 8 13
Weinblatt, 199022 DB 138 6 (0.5-48) 7.5-15 103 0
Mielants, 199124 0 92 12 (1-41) NM 143 4
Scully, 199125 R 124 12 (1-55) Mean 9.9 400 0
Singh, 199128 R 497 14 (NM) Low dose 735 2
Jeurissen, 199127 DB 31 13 (SD 10) 5-15 28 18
Weinblatt, 199229 O 26 9 (1.8-27) 5-15 56 7
Kremer, 199236 0 25 18 {12-28) 7.5-22.5 63 0
Wilkens, 199231 DB 67 10 (1-40) 5-15 35 0
Buchbinder, 199332 R 50 9 (0.3-47) 5-20 780 0
Kerstens, 199416 0 14 16 (5-33) 5-15 57 16
Abbreviations: MTX, methotrexate; O, open prospective; DB, double blind; R, retrospective; NM, not mentioned.
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Table 4: Infection Rate During MTX Treatment in RA in Patients: Reports From the Literature
Comparing Different Study Designs
Study
Design
Patients at 
the Start
Patient 
Years 
on MTX
Infection
Rate Illustrative References
Retrospective 1257 3840 1.8 4, 6, 28, 32
Open 650 1330 4.6 1,3, 11-15, 16, 18,19, 24, 29, 30
Double-blind 441 248.9 11.6 5, 7, 10, 20 ,21 ,22 , 27,31
NOTE. Infection rate -  (number of infections/patient years at risk) x 100. 
Abbreviations; MTX, methotrexate.
due to absence of hematologic status, 1 due to 
higher MTX dose and 1 because of a high dose 
of concommitant steroids4*6,12’14,23*38'47 (Table 5). 
In the remaining 15 case reports the age of the 
patients ranged from 42 to 83 years (mean 62 
years) and the disease duration from 3 to 35 
years (mean 14 years). Opportunistic infections 
were observed after a variable duration of MTX 
treatment (mean ± 20; range 0.9- > 84 
months). Eleven of the 30 patients were not 
using prednisone when the opportunistic infec­
tion was diagnosed. No reports of opportunistic 
infections during A ZA  treatment were found. 
Pneumocystis carinii pneumonia was noted once 
during cyclosporine and MTX treatment in an 
RA patient.58 Gruberg et al59 observed a Nocar- 
dia asteroides infection complicating RA in a 
patient treated with a combination of AZA, 
hydroxychloroquine, prednisone, and MTX. No 
report of tuberculosis in RA  patients treated 
with MTX, AZA, or cyclosporine was found.
Opportunistic Infections in Patients With 
Psoriasis (Arthropathy) Treated With MTX,
AZA or Cyclosporin A
Only six reports were found on opportunistic 
infections in association with the use of MTX in 
the absence of leukopenia in psoriasis and 
psoriatic arthropathy patients (Table
39,43,49,59-61 ^wo psoriatic patients developed
tuberculosis after receiving MTX for 2 and l l/2 
years respectively.62 No such reports were found 
for AZA or cyclosporine. Wallis et al63 de­
scribed a 16-year-old girl with psoriatic arthropa­
thy who developed P carinii pneumonia compli­
cating MTX treatment. This patient developed 
pancytopenia during MTX, high dose nonsteroi­
dal anti-inflammatory drug, and a low-dose 
prednisone treatment. Moreover herpes sim­
plex hepatitis ensued in a patient with psoriatic 
arthritis who developed leukopenia during the 
use of MTX, prednisone, and a nonsteroidal 
anti-inflammatory drugs.64
DISCUSSION
The infection-free survival curves in our open 
MTX study and in the MTX and A ZA  patients 
in the double-blind study were not significantly 
different. In RA  patients the infection rates 
during MTX and AZA  treatment were similar. 
This contrasts with a retrospective analysis of 
RA  patients receiving various second-line agents 
showing 17 infections per 1000 person years on 
MTX compared with a maximum of 5 per 1000 
years on AZA.28 A higher infection rate was 
seen in the 4 years open study, these patients 
having more severe R A  at the start of MTX 
treatment. However the number of patients is 
too small to draw firm conclusions about the 
relation between infection frequency and dis­
ease severity.
Although many patients in the open study 
used prednisone, in contrast to the double-blind 
study, infections happened mostly in patients 
who did not use prednisone. While an associa­
tion between glucocorticoid therapy and in­
creased frequency of infection has been re­
ported,65 a meta-analysis of controlled trials 
using steroids showed no enhanced infection 
rate in patients given less than 10 mg predni­
sone daily or a total dose less than 700 mg.66 
Less than 10 mg of prednisone given once a day 
could not maintain free plasma corticosteroid 
levels sufficient to suppress macrophage func­
tion, and larger steroid doses are required to 
inhibit other host defense mechanisms such as 
chemotaxis or polymorphonuclear killing.67 Thus 
the risk of infection from low-dose corticoste­
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Table 5: Opportunistic Infections Associated With MTX Treatment in RA Patients
Without Leukopenia
Year Study Pathogen
Patient/Disease 
Characteristics
Treatment
Characteristics
Age
Gender (yr)
Disease
Duration
(yr)
MTX 
Weekly 
Dose (mg)
MTX
Duration
(mo)
Prednisone 
Daily Dose 
(mg)
1983 Perroquet38 Pneumocystis carinii F 74 10 15 5 5
1983 Groff4 Varicella zoster 17 8 (max) 7.5 0
Herpes zoster 21 18 (max) 10 5
1985 Weinstein6 V zoster 7.5-15 60
1987 Altz-Smith39 Cryptococus M 53 9 10-12.5 16 0
1987 Gispen12 Listeria monocytogenes F 61 10 10-15 15 5
1988 Weinblatt14 H zoster 7.5-15 +
H zoster 7.5-15 +
1988 Keegan40 Nocard/a brasiliensis M 59 7.5 22 2.5-7.5
1990 Antonelli41 H zoster F 62 16 12.5 48 0
H zoster F 57 5 7.5 11 0
H zoster M 58 5 10 15 7.5
H zoster F 76 35 7.5 22 7.5
H zoster M 52 6 20 8 5-60
H zoster F 56 22 10 36 0
H zoster F 67 25 12.5 60 0
H zoster F 58 15 10 12 7.5
1990 Fürst23 Herpes virus 8.4 6 10
Herpes virus 17.7 9 10
Herpes virus 18.3 9 10
Aspergillus 20.0 0.9 0
Histoplasmosis 17.5 1.4 0
1990 Leff42 P carinii IVI 66 22.5 (max) 6 0
1991 Shiroky43 P carinii F 69 3 10 8 0
H zoster F 69 23 10 8 6-15
H zoster F 83 23 10 > 8 4 5
1991 Wollner44 P carinii F 56 5 7.5 48 2.5
1991 Flood45 P carinii 66 11 12.5 3 12.5
1991 Clerc46 Cytom eg a lo virus 51 8 7.5 24 10
1992 Porter47 P carinii 42 18 7.5 4 0
Abbreviations: MTX, methotrexate.
roids in RA  appears negligible although it might 
be increased in combination with MTX.
Some retrospective studies based on question­
naire design have shown that regardless of 
treatment RA patients are not more susceptible 
to common infections than control patients with 
osteoarthritis or soft tissue rheumatism,68*^  On 
the other hand RA patients have a higher 
percentage of death due to infectious disease 
than the general population.70'72 However, stud­
ies on the cause of mortality in RA  patients may 
deal with patients that required hospitalization 
and have more severe infection, leading to a
higher mortality. This was confirmed by a pro­
spective study of Rasker and Cosh.73
There was a wide range of infection rates in 
data from the literature concerning MTX treat­
ment of RA. Older studies often focused on he­
patic side effects. More recent studies reported 
side effects in more detail with greater emphasis 
on infection. Our results are in accord with 
recent infection rates, (Table 3). An infection 
rate of greater than 13% was found in several 
double blind studies and in only one (our) open 
study15,10 that showed an infection rate of 15.7%. 
All of the patients in this trial had severe dis-
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Table 6: Opportunistic Infections Associated With MTX Treatment in Patients With Psoriasis and
Psoriatic Arthropathy in the Absence of Leukopenia
Patient/Disease 
Characteristics
Treatment Characteristics
MTX Prednisone
Age MTX Weekly Duration Daily Dose
Diagnosis Year Author Pathogen Gender (y r) Dose (mg) (mo) (mg)
Psoriasis 1971 Smith62 Microbacterium
tuberculosis M 48 25*/5 13 NM
M  tuberculosis M 37 25*/20 10 NM
1975 King61 Hepatitis B M 42 NM NM NM
1992 Witty60 Histoplasmosis M 43 7.5 120 NM
Histoplasmosis F 36 7.5 108 NM
Histoplasmosis F 28 10 4 NM
1993 Law49 Cryptococcosis M 81 12.5 8 NM
Psoriatic arthropathy 1987 Altz-Smith39 Cryptococcosis M 45 12.5-15 22 NM
1991 Shiroky43 Herpes zostert F 54 10 12 5
Abbreviations: NM, not mentioned.
in itia l dosage gradually reduced to final dosage.
tLymphopenia: 0.69 x 109/L.
abling RA and most infections occurred in the 
first li/2 years of MTX treatment. The double 
blind studies with a high infection rate have a 
short term follow-up,7’20’21«27 so most infections 
happened in the first year of treatment. This 
finding suggests that MTX has the strongest 
immunosuppressive effect soon after initiation. 
Another possible explanation for a lower infec­
tion rate long term is that if MTX controls the 
disease, the inflammatory activity will be down 
regulated and defense mechanisms restored. 
MTX might be a double edged sword: adversely 
influencing macrophage and granulocyte func­
tion and subsets of T lymphocytes,74’75 while on 
the other hand restoring the immune response/ 
balance by controlling the underlying disease. 
The mechanism of action of MTX is unknown, 
whether primarily anti-inflammatory or immuno­
suppressive, despite several known effects on 
immunoinflammatory processes both in experi­
mental animals and in humans.76’77 T cells have 
a central role in the pathogenesis of RA. During 
MTX treatment serum immunoglobulin lev­
els8,15 and rheumatoid factor27 titers decrease. 
Significant reductions in sIL~2R and p55 concen­
trations were also observed in patients treated 
with MTX, but not with AZA.78 A  reduction of 
granulocyte chemotaxis has also been noted.79
Based on the literature opportunistic infec­
tions are considered a specific side effect of
MTX therapy in RA patients. They were not 
associated with AZA (in RA) and only once 
with combined MTX and cyclosporine treat­
ment.57 Opportunistic infections were reported 
in RA patients treated with cyclophospha­
mide,80"82 but we are not aware of an association 
with other DMARDs. Interestingly, our litera- 
ture search revealed only occasional opportunis­
tic infection in psoriasis and psoriatic arthropa­
thy patients treated with MTX39-43*49*61*64 despite 
the large number of treated patients. Probably 
the underlying immunological disturbance in 
RA patients is more important in this respect, 
as are the modifying effects of MTX on the 
immunological functions.83'86 As with acquired 
immunodeficiency syndrome (AIDS) patients, 
Pneumocystis carinii is the most frequent oppor­
tunistic infection in RA treated with MTX. 
Interestingly, in the literature search we did not 
find tuberculosis in RA patients treated with 
MTX, AZA, or cyclosporine, in contrast with 
AIDS and other immunosuppressed patients.
In conclusion: The most vulnerable phase for 
developing infection during MTX treatment in 
RA is in the first year of treatment. The risk for 
opportunistic infections are not limited to any 
period of treatment. In our studies patients with 
severe RA had more infectious complications 
than patients with moderate RA, although our 
numbers are too small to draw firm conclusions.
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